Scalable Antigen-Antibody Binding Affinity Landscape: A Case Study with ENHERTU

Wei Li

DOI: https://doi.org/10.1101/2024.07.12.603351

2024-07-13

Abstract:Optimization of binding affinities for antibody-drug conjugates (ADCs) is inextricably linked to their therapeutic efficacy and specificity, where the majority of ADCs are engineered to achieve equilibrium dissociation constants (Kd values) in the range of 0.1 to 1 nM. Yet, there is a paucity of published data delineating the optimal binding affinity or its range that ensures improved therapeutic outcomes for ADCs. This study addresses this issue by integrating structural biophysics within a scalable in silico workflow to generate antigen-antibody binding affinity landscapes, with a focus on Trastuzumab, a monoclonal antibody employed in the treatment of HER2-positive breast cancer. By leveraging high-throughput computational techniques, including homology structural modeling and structural biophysics-based Kd calculations, this research puts forward a set of high-accuracy structural and intermolecular binding affinity data for Her2-Trastuzumab-Pertuzumab (PDB entry 6OGE). Beyond the design of Her2-targeting ADCs with enhanced efficacy and specificity, this scalable antigen-antibody binding affinity landscape also offers a technically feasible workflow for the high-throughput generation of synthetic structural and biophysical data with reasonable accuracy. Overall, in combination with artificial intelligence (e.g., deep learning) algorithms, this synthetic data approach aims to catalyze a paradigm shift in the discovery and design of antibodies and ADCs with improved efficacy and specificity.

Biophysics

What problem does this paper attempt to address?

The problem this paper attempts to address is the optimization of the binding affinity of antibody-drug conjugates (ADCs) to enhance their therapeutic efficacy and specificity. Specifically, although most ADCs are designed with a target equilibrium dissociation constant (K_d value) in the range of 10^-9 to 10^-10 molar, there is currently a lack of definitive data to delineate the optimal binding affinity or its range to ensure improved therapeutic outcomes for ADCs. Therefore, this study combines structural biophysics with scalable computational workflows to generate an antigen-antibody binding affinity landscape, using trastuzumab as a case study. The research employs high-throughput computational techniques, including homology structure modeling and structure-based biophysical K_d value calculations, to propose a series of high-precision structures and intermolecular binding affinity data for Her2-trastuzumab-pertuzumab (PDB entry 6OGE). In addition to designing Her2-targeted ADCs with enhanced efficacy and specificity, this scalable antigen-antibody binding affinity landscape provides a technically feasible workflow for efficiently generating synthetic structural and biophysical data with reasonable accuracy. Furthermore, by integrating artificial intelligence (such as deep learning) algorithms, this approach aims to drive a paradigm shift in the field of antibody and ADC discovery and design.